N. Awad

Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

W. Blackwelder, K. Ella, S. Panda, 2021, The Lancet.